Search Autoimmune Association
Share this article

CMS Drops Stacking Provision in Medicaid Drug Rebate Proposal

 

The Autoimmune Association, along with 31 other patient organizations, submitted a letter to request the Centers for Medicare & Medicaid Services (CMS) to withdraw the Medicaid Rebate Stacking Policy from Medicaid Drug Rebate Program (MDRP) to protect patients and providers access to medications. We are happy to report that on May 15 CMS responded and indicated that they are not finalizing the proposal regarding stacking at this time.

CMS Image

With the proposed policy change, titled “Misclassification of Drugs, Program Administration and Program Integrity Updates under the Medicaid Drug Rebate Program,” the best price reporting mechanisms would change for manufacturers, posing a significant level of uncertainty in terms of access for patients. While the Autoimmune Association respects the intent of this policy, we had some significant concerns about potential unintended consequences. We are pleased CMS is instead working with pharmaceutical manufacturers to collect additional information related to best price stacking methodologies to better understand and inform future rule-making.

The letter, submitted in mid-April,  detailed that the signers had concern about medication manufacturers reducing or eliminating discounts in the supply chain, further causing ripples and ultimately causing risk for an untenable healthcare situation. Patients are already experiencing higher rates of step therapy and prior authorization, which are creating increased access challenges for many people. The letter encouraged CMS to withdraw this policy and work closely with patients and providers to ensure that well-intentioned policies truly benefit all stakeholders.

We applaud CMS for taking the time to collect more information and look forward to working together on policies that lower access issues and burden for patients in the future.

Further reading:

  • Full letter to HHS and CMS can be found here.
  • CMS Statement on Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program (MDRP) Proposed Rule (CMS-2434-P) can be found here.

 

Share this article

Join our email list

Receive the latest blog articles, news, and more right to your inbox!

Related articles you might be interested in

Autoimmune Association Image Do Not Touch

Raising Voices on Capitol Hill: Our Inaugural Legislative Fly-In

  This month marked a groundbreaking moment as we hosted our inaugural Legislative Fly-In, an inspiring day in Washington, D.C. where 20 passionate...
Autoimmune Association Image Do Not Touch

Get Involved During Autoimmune Awareness Month

  Celebrated every March, Autoimmune Awareness Month is dedicated to enhancing understanding and recognition of autoimmune diseases. These are conditions where the immune...
Autoimmune Association Image Do Not Touch

Autoimmune Association Advocates for Federal Legislation to Reform Harmful PBM Practices

What are Pharmacy Benefit Managers (PBMs)? Pharmacy Benefit Managers, or PBMs, are entities that handle prescription drug benefits for health insurance plans. They...
Autoimmune Association Image Do Not Touch

Inflation Reduction Act (IRA) Medicare Drug Price Negotiation List Announced

Today, the Centers for Medicare & Medicaid Services (CMS) released the list of medicines it will start directly negotiating within Medicare Part D....

Find more resources on autoimmunity

Learn more about autoimmunity, diagnosis tips, how to find a physician, and more.